



## **Open Monoclonal Technology announces further intellectual property strengthening**

**Palo Alto, California, December 9, 2014**

Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic animals for discovery of human therapeutic antibodies, today announced further strengthening of the intellectual property related to the company's core technology.

The US Patent Office today issued US patent number 8,907,157 related to novel genetic engineering methods for the generation of rodents expressing human antibodies. This follows the April 22 2014 issuance of US patent number 8,703,485 related to inactivation of rodent immunoglobulin genes. These patents and foreign equivalents strengthen the intellectual property position of all OMT's platforms.

Dr. Roland Buelow, founder and CEO of OMT, said "OMT was founded to become a leader in transgenic animal-based human therapeutic antibody platforms. We are the only company commercially offering transgenic rats and mice with global patent protection and freedom-to-operate in this space. OMT is profitable and well positioned to continue growing its leadership position."

### **About Open Monoclonal Technology**

Open Monoclonal Technology, Inc. (OMT) is a leader in genetic engineering of animals for creation of human therapeutic antibodies, *naturally optimized human antibodies*<sup>®</sup>, and the only company in the world with three transgenic animal platforms, *OmniAb*<sup>™</sup>.

*OmniRat*<sup>®</sup> is the industry's first human monoclonal antibody technology based on rats. It has a complete immune system with a diverse antibody repertoire and generates antibodies with human idiotypes as well as wild-type animals make rat antibodies. *OmniMouse*<sup>®</sup> is a transgenic mouse that complements OmniRat and expands epitope coverage. Both deliver human antibodies with high affinity, specificity, expression, solubility and stability. *OmniFlic*<sup>™</sup> is the first engineered rat with a fixed light chain for development of bispecific, fully human antibodies.

All four OmniAb<sup>™</sup> platforms use patented technology, have broad freedom to operate and are available worldwide for all targets and indications. Current partners include Chugai, Genmab, Genentech, HanAll, Janssen, Merck KGaA, Pfizer, Roche, Symphogen, an undisclosed global pharmaceutical company and several smaller biotech companies and universities. OmniAb antibody discovery services are also available via Antibody Solutions in the US, Aldevron in Germany and WuXi AppTec in China.

For more information, please visit [www.omtinc.net](http://www.omtinc.net) or contact Chief Business Officer Brian Lundstrom, Phone: +1-775-420-7750, E-mail: [bl@omtinc.net](mailto:bl@omtinc.net).

-- # # # --